Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?

This article was originally published in The Pink Sheet Daily

Executive Summary

Top-line results from the Phase III ARISTOTLE trial show the novel anticoagulant was superior to warfarin on safety and efficacy - a pleasant surprise for investors.
Advertisement

Related Content

Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?
NICE Demands "Less Biased" Cost Data On Pradaxa For AF
Bristol's Yervoy Bursts Out Of The Gate
Final APPRAISE-al: Trial Report Argues Against Anticoagulant/Antiplatelet Combos In ACS
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk
Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS072411

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel